All Trials

A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec Followed by Platinum-doublet Chemotherapy and Bevacizumab Compared With Physician's Choice of Chemotherapy and Bevacizumab in Women With Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Women with platinum-resistant or refractory high‑grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (ECOG 0–1, prior bevacizumab, ≥3 prior lines, measurable peritoneal disease) are randomized to intraperitoneal olvimulogene nanivacirepvec (oncolytic vaccinia immunotherapy) followed by platinum-doublet chemotherapy plus bevacizumab versus physician’s choice chemotherapy plus bevacizumab. Investigational Olvi‑Vec is designed to selectively replicate in tumor cells to induce oncolysis and stimulate antitumor immunity.

ClinicalTrials.gov ID: NCT05281471

Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Single-arm study for adult women with recurrent ovarian, fallopian tube, or primary peritoneal carcinoma (platinum-sensitive or -resistant) with prior PARP inhibitor exposure, ECOG 0–1, and measurable disease. Patients receive oral ZEN003694 (pan-BET bromodomain inhibitor targeting BRD2/3/4/BRDT to downregulate HR/MYC programs) plus talazoparib (PARP inhibitor) in 28-day cycles; BRCA status known but not restricted.

ClinicalTrials.gov ID: NCT05071937

A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic cutaneous (including acral) melanoma who are HLA‑A*02:01 positive and have progressed after PD‑1 therapy (and BRAF‑directed therapy if mutated) are randomized to autologous PRAME‑targeted TCR‑T cells (IMA203) after lymphodepletion with short-course low‑dose IL‑2 support versus investigator’s choice of approved therapies (e.g., nivolumab/relatlimab, anti‑PD‑1, ipilimumab, lifileucel, or chemotherapy). Key exclusions include mucosal/uveal melanoma, active CNS disease, significant autoimmune/cardiac comorbidities, active infections, and LDH >2× ULN.

ClinicalTrials.gov ID: NCT06743126

A Multicenter, Phase II Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with non-uveal melanoma and measurable untreated brain metastases (including asymptomatic ECOG 0–1 and symptomatic ECOG 0–2 with limited steroids) receive triple checkpoint blockade: nivolumab (PD-1 inhibitor) plus relatlimab (LAG-3 inhibitor) combined with ipilimumab (CTLA-4 inhibitor). Prior adjuvant/neoadjuvant PD-1/CTLA-4/LAG-3 allowed if >6 months; excludes leptomeningeal disease, prior whole-brain RT, active autoimmune disease requiring systemic therapy, and significant cardiac comorbidity.

ClinicalTrials.gov ID: NCT06712927

A Phase II, Multicenter, Open-Label Trial of DB-1311 in Combination With BNT327 or DB-1305 in Participants With Advanced/Metastatic Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with advanced/metastatic solid tumors—HCC (Child-Pugh A), cervical, melanoma, recurrent/metastatic HNSCC, platinum‑resistant high‑grade serous ovarian, and nonsquamous NSCLC without actionable drivers—ECOG 0–1 and measurable disease. Investigational therapy pairs the B7‑H3–targeted topoisomerase‑I ADC DB‑1311 with either BNT327 (PD‑L1/VEGF‑A bispecific) for HCC/cervical/melanoma/HNSCC or with the TROP2‑directed topoisomerase‑I ADC DB‑1305 for NSCLC.

ClinicalTrials.gov ID: NCT06953089

An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally advanced/metastatic NSCLC enrolled by biomarker and line: first-line AGA-negative with PD-L1 ≥50% get rilvegostomig (PD‑1/TIGIT bispecific) ± ramucirumab, first-line AGA-negative with PD-L1 1–49% get rilvegostomig + ramucirumab, and second-line AGA-positive nonsquamous post–targeted therapy get datopotamab deruxtecan (TROP2 ADC) + ramucirumab ± rilvegostomig. Designed to assess safety and antitumor activity across these combinations, excluding patients with active autoimmune disease, uncontrolled comorbidities, or unstable CNS disease.

ClinicalTrials.gov ID: NCT07098338

A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients With Metastatic Castration-Resistant Prostate Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: mCRPC patients with adenocarcinoma after exactly one prior second‑generation ARSI and no taxane in the mCRPC setting receive the CD46‑targeted antibody‑drug conjugate FG‑3246 (FOR46), an MMAE‑conjugated monoclonal antibody, given IV every 3 weeks at randomized doses (1.8, 2.4, or 2.7 mg/kg). Requires recent CRPC‑era tissue, measurable/evaluable disease, and excludes prior CD46 therapy, neuroendocrine histology, >1 ARSI, significant neuropathy, or recent systemic therapy.

ClinicalTrials.gov ID: NCT06842498

A Phase IIIb, Open-label, Multinational Study Assessing the Efficacy and Safety of Dato-DXd Treatment in Patients With HRpositive, HER2 IHC 0, Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy (TROPION-Breast06)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with endocrine-refractory HR-positive (ER and/or PgR ≥1%), HER2 IHC 0 locally advanced inoperable or metastatic breast cancer, ECOG 0–1, with no prior chemotherapy for metastatic disease and no prior TROP2-targeted or topoisomerase I inhibitor–containing therapy. All participants receive datopotamab deruxtecan 6 mg/kg IV every 3 weeks, a TROP2-directed antibody–drug conjugate delivering a topoisomerase I inhibitor (DXd) payload, continued until progression or unacceptable toxicity.

ClinicalTrials.gov ID: NCT07205822

A Randomized, Open-label, Phase 2b Study to Compare the Efficacy of DSP107 in Combination With Atezolizumab Versus Fruquintinib in Patients With Advanced Microsatellite Stable Colorectal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with inoperable/metastatic microsatellite-stable (pMMR) colorectal cancer with measurable disease who progressed on/intolerant to standard therapies and have had ≤3 prior lines (no prior fruquintinib or regorafenib; limited prior targeted therapy allowed for select biomarker-defined subgroups) are randomized 1:1. Treatment compares atezolizumab plus DSP107 (a CD47-blocking SIRPα fusion protein delivering tumor-anchored 4-1BBL costimulation to enhance innate phagocytosis and T-cell activation) versus oral fruquintinib (VEGFR TKI).

ClinicalTrials.gov ID: NCT07235293

KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolls adults with previously untreated advanced/metastatic nonsquamous NSCLC harboring a KRAS G12C mutation (tumor tissue or ctDNA), requiring available archival/new non-irradiated tumor tissue and excluding prior KRAS-targeted therapy or active CNS disease. Randomizes first-line treatment to pembrolizumab + carboplatin/pemetrexed vs pembrolizumab plus MK-1084 (selective covalent KRAS G12C-GDP inhibitor) vs pembrolizumab + MK-1084 + cetuximab (EGFR antibody).

ClinicalTrials.gov ID: NCT07252739